Drugs / Trimegestone
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03343912 | Nov 2017 → Jan 2018 | pregnancy disorder | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00195455 | Feb 2005 → Mar 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00472004 Comparator | Feb 2006 → Dec 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimegestone | “17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration” NCT00472004 ↗ |
| Known as | RU 27987 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104765 ↗ |
| Known as | TMG | “Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application” NCT03343912 ↗1“17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration” NCT00472004 ↗ |
| Known as | Trimegestona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2104765 ↗ |
| Action | Activate | “Progesterone receptor agonist” CHEMBL2104765 ↗ |
| Modality | Small molecule | — CHEMBL2104765 ↗ |
| Route | Other | “vaginal application” NCT03343912 ↗ |
| Target | PGR | “Progesterone receptor agonist” CHEMBL2104765 ↗ |